Patents by Inventor Guangning Ma

Guangning Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidine compounds useful as tyrosine kinase inhibitors
    Patent number: 11708335
    Abstract: The present disclosure provides pyrimidine compounds useful as tyrosine kinase inhibitors, and particularly epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors. The disclosed EGFR inhibitors are effective against acquired resistance mutations appearing after treatment of existing EGFR inhibitors. The present disclosure also provides methods of treating cancer using pyrimidine compounds and pharmaceutical compositions comprising pyrimidine compounds. The methods of treating cancer may be directed to cancer with acquired resistance mutations.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: July 25, 2023
    Assignee: SternGreene, Inc.
    Inventors: Lihu Yang, Guangning Ma, Yingjie Cui
  • Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
    Patent number: 11524960
    Abstract: The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 13, 2022
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventors: Zenon D. Konteatis, Mingzong Li, Peng Liu, Matthew Medeiros, Samuel K. Reznik, Zhihua Sui, Jeremy M. Travins, Janeta Popovici-Muller, Shubao Zhou, Guangning Ma
  • HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER
    Publication number: 20210115045
    Abstract: The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.
    Type: Application
    Filed: March 28, 2019
    Publication date: April 22, 2021
    Inventors: Zenon D. KONTEATIS, Mingzong LI, Peng LIU, Matthew MEDEIROS, Samuel K. REZNIK, Zhihua SUI, Jeremy M. TRAVINS, Janeta POPOVICI-MULLER, Shubao ZHOU, Guangning MA
  • PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
    Publication number: 20210094923
    Abstract: The present disclosure provides pyrimidine compounds useful as tyrosine kinase inhibitors, and particularly epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors. The disclosed EGFR inhibitors are effective against acquired resistance mutations appearing after treatment of existing EGFR inhibitors. The present disclosure also provides methods of treating cancer using pyrimidine compounds and pharmaceutical compositions comprising pyrimidine compounds. The methods of treating cancer may be directed to cancer with acquired resistance mutations.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 1, 2021
    Inventors: Lihu Yang, Guangning Ma, Yingjie Cui